Equities

Jiangsu Kanion Pharmaceutical Co Ltd

600557:SHH

Jiangsu Kanion Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)11.98
  • Today's Change-0.22 / -1.80%
  • Shares traded8.28m
  • 1 Year change-32.43%
  • Beta0.9757
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,4291,7711,113
Total Receivables, Net1,1041,4821,366
Total Inventory350343338
Prepaid expenses9913457
Other current assets, total67----
Total current assets4,0503,7302,874
Property, plant & equipment, net2,5642,5292,554
Goodwill, net595959
Intangibles, net369398434
Long term investments154661
Note receivable - long term------
Other long term assets------
Total assets7,1176,7966,018
LIABILITIES
Accounts payable228362321
Accrued expenses1,030843534
Notes payable/short-term debt012274
Current portion long-term debt/capital leases------
Other current liabilities, total350565324
Total current liabilities1,6091,7811,453
Total long term debt000
Total debt012274
Deferred income tax------
Minority interest188180168
Other liabilities, total1288192
Total liabilities1,9252,0421,714
SHAREHOLDERS EQUITY
Common stock585585593
Additional paid-in capital11298172
Retained earnings (accumulated deficit)4,5444,1363,720
Treasury stock - common(48)(65)(180)
Unrealized gain (loss)------
Other equity, total------
Total equity5,1934,7544,304
Total liabilities & shareholders' equity7,1176,7966,018
Total common shares outstanding578576576
Treasury shares - common primary issue6.258.1716
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.